221 related articles for article (PubMed ID: 30689386)
1. The Alkyne Moiety as a Latent Electrophile in Irreversible Covalent Small Molecule Inhibitors of Cathepsin K.
Mons E; Jansen IDC; Loboda J; van Doodewaerd BR; Hermans J; Verdoes M; van Boeckel CAA; van Veelen PA; Turk B; Turk D; Ovaa H
J Am Chem Soc; 2019 Feb; 141(8):3507-3514. PubMed ID: 30689386
[TBL] [Abstract][Full Text] [Related]
2. Identification of new peptide amides as selective cathepsin L inhibitors: the first step towards selective irreversible inhibitors?
Torkar A; Lenarčič B; Lah T; Dive V; Devel L
Bioorg Med Chem Lett; 2013 May; 23(10):2968-73. PubMed ID: 23562595
[TBL] [Abstract][Full Text] [Related]
3. Influence of azide incorporation on binding affinity by small papain inhibitors.
Wammes AE; Hendriks TG; Amatdjais-Groenen HI; Wijdeven MA; van Hest JC; van Delft FL; Ritschel T; Rutjes FP
Bioorg Med Chem; 2014 Oct; 22(20):5593-603. PubMed ID: 24972724
[TBL] [Abstract][Full Text] [Related]
4. Advances in the discovery of cathepsin K inhibitors on bone resorption.
Lu J; Wang M; Wang Z; Fu Z; Lu A; Zhang G
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):890-904. PubMed ID: 29723068
[TBL] [Abstract][Full Text] [Related]
5. Dioxo-triazines as a novel series of cathepsin K inhibitors.
Rankovic Z; Cai J; Fradera X; Dempster M; Mistry A; Mitchell A; Long C; Hamilton E; King A; Boucharens S; Jamieson C; Gillespie J; Cumming I; Uitdehaag J; van Zeeland M
Bioorg Med Chem Lett; 2010 Mar; 20(5):1488-90. PubMed ID: 20153187
[TBL] [Abstract][Full Text] [Related]
6. Green asymmetric synthesis of epoxypeptidomimetics and evaluation as human cathepsin K inhibitors.
Silva TL; Dos Santos DA; de Jesus HCR; Brömme D; Fernandes JB; Paixão MW; Corrêa AG; Vieira PC
Bioorg Med Chem; 2020 Aug; 28(15):115597. PubMed ID: 32631567
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological inhibition of cathepsin K: A promising novel approach for postmenopausal osteoporosis therapy.
Mukherjee K; Chattopadhyay N
Biochem Pharmacol; 2016 Oct; 117():10-9. PubMed ID: 27106079
[TBL] [Abstract][Full Text] [Related]
8. Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L.
Falgueyret JP; Oballa RM; Okamoto O; Wesolowski G; Aubin Y; Rydzewski RM; Prasit P; Riendeau D; Rodan SB; Percival MD
J Med Chem; 2001 Jan; 44(1):94-104. PubMed ID: 11141092
[TBL] [Abstract][Full Text] [Related]
9. Dipeptide-derived nitriles containing additional electrophilic sites: potentially irreversible inhibitors of cysteine proteases.
Löser R; Gütschow M
J Enzyme Inhib Med Chem; 2009 Dec; 24(6):1245-52. PubMed ID: 19912058
[TBL] [Abstract][Full Text] [Related]
10. Peptidomimetic inhibitors of cathepsin K.
Black WC
Curr Top Med Chem; 2010; 10(7):745-51. PubMed ID: 20337585
[TBL] [Abstract][Full Text] [Related]
11. Benzodioxocin-3-ones and N-acyl-3-amino-3-buten-2-ones: novel classes of cathepsin K cysteine protease inhibitors.
Yamashita DS; Xie R; Lin H; Wang B; Shi SD; Quinn CJ; Hemling ME; Hissong C; Tomaszek TA; Veber DF
J Pept Res; 2004 Mar; 63(3):265-9. PubMed ID: 15049838
[TBL] [Abstract][Full Text] [Related]
12. Covalent inhibition of SUMO and ubiquitin-specific cysteine proteases by an in situ thiol-alkyne addition.
Sommer S; Weikart ND; Linne U; Mootz HD
Bioorg Med Chem; 2013 May; 21(9):2511-7. PubMed ID: 23535560
[TBL] [Abstract][Full Text] [Related]
13. A composite docking approach for the identification and characterization of ectosteric inhibitors of cathepsin K.
Law S; Panwar P; Li J; Aguda AH; Jamroz A; Guido RVC; Brömme D
PLoS One; 2017; 12(10):e0186869. PubMed ID: 29088253
[TBL] [Abstract][Full Text] [Related]
14. Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitors.
Rankovic Z; Cai J; Kerr J; Fradera X; Robinson J; Mistry A; Hamilton E; McGarry G; Andrews F; Caulfield W; Cumming I; Dempster M; Waller J; Scullion P; Martin I; Mitchell A; Long C; Baugh M; Westwood P; Kinghorn E; Bruin J; Hamilton W; Uitdehaag J; van Zeeland M; Potin D; Saniere L; Fouquet A; Chevallier F; Deronzier H; Dorleans C; Nicolai E
Bioorg Med Chem Lett; 2010 Mar; 20(5):1524-7. PubMed ID: 20149657
[TBL] [Abstract][Full Text] [Related]
15. An Activity-Based Probe for Cathepsin K Imaging with Excellent Potency and Selectivity.
Lemke C; Benýšek J; Brajtenbach D; Breuer C; Jílková A; Horn M; Buša M; Ulrychová L; Illies A; Kubatzky KF; Bartz U; Mareš M; Gütschow M
J Med Chem; 2021 Sep; 64(18):13793-13806. PubMed ID: 34473502
[TBL] [Abstract][Full Text] [Related]
16. Highly selective azadipeptide nitrile inhibitors for cathepsin K: design, synthesis and activity assays.
Ren XF; Li HW; Fang X; Wu Y; Wang L; Zou S
Org Biomol Chem; 2013 Feb; 11(7):1143-8. PubMed ID: 23299878
[TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of the novel reversible and selective cathepsin X inhibitors.
Fonović UP; Mitrović A; Knez D; Jakoš T; Pišlar A; Brus B; Doljak B; Stojan J; Žakelj S; Trontelj J; Gobec S; Kos J
Sci Rep; 2017 Sep; 7(1):11459. PubMed ID: 28904354
[TBL] [Abstract][Full Text] [Related]
18. Cathepsin K inhibitors: a novel target but promising approach in the treatment of osteoporosis.
Helali AM; Iti FM; Mohamed IN
Curr Drug Targets; 2013 Dec; 14(13):1591-600. PubMed ID: 23957815
[TBL] [Abstract][Full Text] [Related]
19. Non-covalent cathepsin K inhibitors for the treatment of osteoporosis.
Kim TS; Tasker AS
Curr Top Med Chem; 2006; 6(4):355-60. PubMed ID: 16611147
[TBL] [Abstract][Full Text] [Related]
20. Cathepsin K inhibitors for osteoporosis and potential off-target effects.
Brömme D; Lecaille F
Expert Opin Investig Drugs; 2009 May; 18(5):585-600. PubMed ID: 19388876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
